We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Wegovy improved functional class vs. placebo at 1 year ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today ...
Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have ...
Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...
Right ventricular systolic function evaluated through VO2 max is a more accurate measure of functional capacity of persons with heart failure compared with left ventricular systolic function. This ...
Adding ertugliflozin (Steglatro; Merck Sharp & Dohme), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to other therapies significantly reduces functional mitral regurgitation (MR) secondary to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback